{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:00:46Z","timestamp":1792450846329,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bcp.2020.114156","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:40:19Z","timestamp":1594950019000},"page":"114156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function"],"prefix":"10.1016","volume":"180","author":[{"given":"Xaria X.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avril A.B.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent M.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114156_b0005","doi-asserted-by":"crossref","first-page":"35518","DOI":"10.1074\/jbc.M405878200","article-title":"Differential Kinetic and Spatial Patterns of \u03b2-Arrestin and G Protein-mediated ERK Activation by the Angiotensin II Receptor","volume":"279","author":"Ahn","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114156_b0010","unstructured":"Australian New Zealand Clinical Trials Registry, 2020. A randomised, double-blind, placebo-controlled, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of PMX205 in healthy volunteers. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=378702 (accessed 10 June 2020)."},{"key":"10.1016\/j.bcp.2020.114156_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00491","article-title":"Macrophage cytokines: involvement in immunity and infectious diseases","volume":"5","author":"Arango Duque","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0020","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/eji.201546131","article-title":"A novel \u201ccomplement-metabolism-inflammasome axis\u201d as a key regulator of immune cell effector function","volume":"46","author":"Arbore","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad1210","article-title":"T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells","volume":"352","author":"Arbore","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bcp.2020.114156_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164646","article-title":"Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study","volume":"11","author":"Bekker","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2020.114156_b0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000057320","article-title":"Diversity of G Protein-Coupled Receptor Signaling Pathways to ERK\/MAP Kinase","volume":"11","author":"Belcheva","year":"2002","journal-title":"Neurosignals"},{"key":"10.1016\/j.bcp.2020.114156_b0040","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/eji.201243075","article-title":"C5a interaction with both C5aR and C5L2 receptors is required for production of G-CSF during the acute inflammatory response","volume":"43","author":"Bosmann","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12640-019-00026-w","article-title":"The Novel C5aR Antagonist DF3016A Protects Neurons Against Ischemic Neuroinflammatory Injury","volume":"36","author":"Brandolini","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bcp.2020.114156_b0050","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/jpet.108.141572","article-title":"Identification and Characterization of NDT 9513727 [N, N-bis(1,3-Benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a Novel, Orally Bioavailable C5a Receptor Inverse Agonist","volume":"327","author":"Brodbeck","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114156_b0055","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature05559","article-title":"C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a","volume":"446","author":"Chen","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114156_b0065","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug-target residence time and its implications for lead optimization","volume":"5","author":"Copeland","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2020.114156_b0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/icb.2013.48","article-title":"C5a, but not C5a-des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2","volume":"91","author":"Croker","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bcp.2020.114156_b0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/icb.2014.32","article-title":"C5a2 can modulate ERK1\/2 signaling in macrophages via heteromer formation with C5a1 and [beta]-arrestin recruitment","volume":"92","author":"Croker","year":"2014","journal-title":"Immunol. Cell Biol."},{"issue":"8","key":"10.1016\/j.bcp.2020.114156_b0080","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/icb.2016.43","article-title":"Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling","volume":"94","author":"Croker","year":"2016","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.bcp.2020.114156_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109764","article-title":"Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor","volume":"123","author":"D\u2019Angelo","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2020.114156_b0090","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1021\/jm9806594","article-title":"Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a","volume":"42","author":"Finch","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114156_b0095","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.4049\/jimmunol.0901005","article-title":"Treatment with a C5aR Antagonist Decreases Pathology and Enhances Behavioral Performance in Murine Models of Alzheimer\u2019s Disease","volume":"183","author":"Fonseca","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0100","doi-asserted-by":"crossref","unstructured":"C. Yan H. Gao New insights for C5a and C5a receptors in sepsis Front. Immun. 3 10.3389\/fimmu.2012.00368 http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2012.00368\/abstract.","DOI":"10.3389\/fimmu.2012.00368"},{"key":"10.1016\/j.bcp.2020.114156_b0105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0702849","article-title":"Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells","volume":"128","author":"Gazi","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0110","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","article-title":"Role of C5a in inflammatory responses","volume":"23","author":"Guo","year":"2005","journal-title":"Ann. Rev. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0115","doi-asserted-by":"crossref","DOI":"10.3390\/bios2030273","article-title":"A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling","volume":"2","author":"Halai","year":"2012","journal-title":"Biosensors"},{"key":"10.1016\/j.bcp.2020.114156_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molimm.2016.11.010","article-title":"Complement in the fundamental processes of the cell","volume":"84","author":"Hawksworth","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.molimm.2017.05.015","article-title":"New concepts on the therapeutic control of complement anaphylatoxin receptors","volume":"89","author":"Hawksworth","year":"2017","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0130","doi-asserted-by":"crossref","first-page":"e01755","DOI":"10.1128\/mBio.01755-17","article-title":"Complement C5a Receptor 1 Exacerbates the Pathophysiology of N. meningitidis Sepsis and Is a Potential Target for Disease Treatment","volume":"9","author":"Herrmann","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.bcp.2020.114156_b0135","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1124\/mol.115.099671","article-title":"Ligand Residence Time at G-protein\u2013Coupled Receptors\u2014Why We Should Take Our Time To Study It","volume":"88","author":"Hoffmann","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drudis.2015.07.015","article-title":"Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?","volume":"21","author":"Hothersall","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bcp.2020.114156_b0145","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/mol.104.006270","article-title":"\u03b2-Arrestin 2-Dependent Angiotensin II Type 1A Receptor-Mediated Pathway of Chemotaxis","volume":"67","author":"Hunton","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","article-title":"From Monocytes to M1\/M2 Macrophages: Phenotypical vs Functional Differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0155","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1476-5381.2012.02183.x","article-title":"The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10","volume":"168","author":"Jain","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0160","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1124\/pr.111.005223","article-title":"International Union of Basic and Clinical Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors","volume":"65","author":"Klos","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2020.114156_b0165","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/acsomega.9b03735","article-title":"Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice","volume":"5","author":"Kumar","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2020.114156_b0170","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1038\/s41598-018-26387-4","article-title":"Development and validation of a LC-MS\/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice","volume":"8","author":"Kumar","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114156_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101340","article-title":"Complement dysregulation in the central nervous system during development and disease","volume":"45","author":"Lee","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0180","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bph.13730","article-title":"Pharmacological inhibition of complement C5a\u2013C5aR1 signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"174","author":"Lee","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0185","first-page":"ji2000407","article-title":"C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages","author":"Li","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0190","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","article-title":"The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity","volume":"202","author":"Li","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0195","unstructured":"[dataset] Li, X.X., Lee, J.D., Massey, N.L., Guan, C., Robertson, A.A.B., Clark, R.J., Woodruff, T.M., 2020b. Chemical synthesis methods for the C5aR1 inhibitor DF2593A. DOI 10.17605\/OSF.IO\/24W9J."},{"key":"10.1016\/j.bcp.2020.114156_b0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41594-018-0067-z","article-title":"Orthosteric and allosteric action of the C5a receptor antagonists","volume":"25","author":"Liu","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2020.114156_b0205","first-page":"1","article-title":"Complement: Bridging the innate and adaptive immune systems in sterile inflammation","volume":"2020","author":"Lo","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2020.114156_b0210","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.biocel.2009.04.005","article-title":"Complement component 5a (C5a)","volume":"41","author":"Manthey","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2020.114156_b0215","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1124\/mol.65.4.868","article-title":"Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and Activity","volume":"65","author":"March","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.imlet.2005.03.003","article-title":"The C3a receptor antagonist SB 290157 has agonist activity","volume":"100","author":"Mathieu","year":"2005","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bcp.2020.114156_b0225","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1042\/bj2950679","article-title":"Characterization of a complement-fragment-C5a-stimulated calcium-influx mechanism in U937 monocytic cells","volume":"295","author":"Monk","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2020.114156_b0230","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.bjp.0707332","article-title":"Function, structure and therapeutic potential of complement C5a receptors","volume":"152","author":"Monk","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0235","doi-asserted-by":"crossref","first-page":"16937","DOI":"10.1073\/pnas.1417365111","article-title":"Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief","volume":"111","author":"Moriconi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2020.114156_b0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2020.114156_b0245","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/sj.bjp.0702938","article-title":"Pharmacological characterization of antagonists of the C5a receptor","volume":"128","author":"Paczkowski","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0250","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1074\/jbc.RA119.007485","article-title":"Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1","volume":"294","author":"Pandey","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114156_b0255","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.tibs.2020.04.004","article-title":"Emerging Insights into the Structure and Function of Complement C5a Receptors","volume":"45","author":"Pandey","year":"2020","journal-title":"Trends. Biochem. Sci."},{"key":"10.1016\/j.bcp.2020.114156_b0260","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2362.2004.01273.x","article-title":"C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway","volume":"34","author":"Perianayagam","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114156_b0265","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molimm.2009.08.032","article-title":"Recent Developments in Low Molecular Weight Complement Inhibitors","volume":"47","author":"Qu","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1189\/jlb.69.1.3","article-title":"MAP kinase activation in macrophages","volume":"69","author":"Rao","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2020.114156_b0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bcp.2020.114156_b0280","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature25025","article-title":"Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727","volume":"553","author":"Robertson","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114156_b0285","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1016\/j.bmcl.2006.07.036","article-title":"Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: Increased receptor specificity and in vivo activity","volume":"16","author":"Schnatbaum","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2020.114156_b0290","doi-asserted-by":"crossref","first-page":"24575","DOI":"10.1038\/srep24575","article-title":"Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists","volume":"6","author":"Seow","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114156_b0295","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.4049\/jimmunol.1301355","article-title":"Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a","volume":"191","author":"Seow","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0300","doi-asserted-by":"crossref","unstructured":"Shapira, M.a., Vogel, Z., Sarne, Y., 2000. Opioid and Cannabinoid Receptors Share a Common Pool of GTP-Binding Proteins in Cotransfected Cells, But Not in Cells Which Endogenously Coexpress the Receptors. Cell Mol Neurobiol 20, 291-304.","DOI":"10.1023\/A:1007058008477"},{"key":"10.1016\/j.bcp.2020.114156_b0305","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1074\/jbc.M506576200","article-title":"\u03b2-Arrestin-dependent, G Protein-independent ERK1\/2 Activation by the \u03b22 Adrenergic Receptor","volume":"281","author":"Shenoy","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114156_b0310","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.4049\/jimmunol.174.5.3041","article-title":"Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha(i2) activation that controls C5aR and Fc receptor cooperation","volume":"174","author":"Skokowa","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0315","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.intimp.2014.05.008","article-title":"Treatment with the C5a Receptor\/CD88 Antagonist PMX205 Reduces Inflammation in a Murine Model of Allergic Asthma","volume":"21","author":"Staab","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2020.114156_b0320","doi-asserted-by":"crossref","first-page":"49403","DOI":"10.1074\/jbc.M209672200","article-title":"Identification of a potent and orally active non-peptide C5a receptor antagonist","volume":"277","author":"Sumichika","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2020.114156_b0325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molimm.2018.06.264","article-title":"New tricks for an ancient system: Physiological and pathological roles of complement in the CNS","volume":"102","author":"Tenner","year":"2018","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0330","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/13543784.2018.1472234","article-title":"Avacopan in the treatment of ANCA-associated vasculitis","volume":"27","author":"Tesar","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.bcp.2020.114156_b0335","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bcp.2020.114156_b0340","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1269","article-title":"The dark side of C5a in sepsis","volume":"4","author":"Ward","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0345","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/sj.bjp.0703394","article-title":"5-HT(1A) receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems","volume":"130","author":"Watson","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2020.114156_b0350","first-page":"1407","article-title":"Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration","volume":"20","author":"Woodruff","year":"2006","journal-title":"FASEB J. Offi. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.bcp.2020.114156_b0355","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.molimm.2011.04.014","article-title":"Inhibiting the C5\u2013C5a receptor axis","volume":"48","author":"Woodruff","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2020.114156_b0360","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/jpet.105.086835","article-title":"Increased Potency of a Novel Complement Factor 5a Receptor Antagonist in a Rat Model of Inflammatory Bowel Disease","volume":"314","author":"Woodruff","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2020.114156_b0365","article-title":"The Interaction between Circulating Complement Proteins and Cutaneous Microvascular Endothelial Cells in the Development of Childhood Henoch-Sch\u00f6nlein Purpura","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2020.114156_b0370","doi-asserted-by":"crossref","first-page":"R140","DOI":"10.1186\/ar3873","article-title":"C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"14","author":"Yuan","year":"2012","journal-title":"Arthritis. Res. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:20:12Z","timestamp":1757769612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220303920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":73,"alternative-id":["S0006295220303920"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114156","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114156"}}